Document is current
Any future updates will be listed below
-
Authors
Prétot, Dominique
della Volpe Waizel, Maria
Kaminska, Karolina
Valmaggia, Philippe
Placidi, Giorgio
Falsini, Benedetto
Fries, Fabian N.
Szentmáry, Nóra
Rivolta, Carlo
Scholl, Hendrik P. N.
Calzetti, Giacomo https://orcid.org/0000-0003-1391-9510
-
Funding
Funding for this research was provided by:
University of Basel
- License Information
-
More Information
Article History
Received: 7 May 2024
Revised: 13 September 2024
Accepted: 3 October 2024
First Online: 12 October 2024
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical Approval was provided by Ethics Commission of Central and Northern Switzerland (EKNZ Basel Switzerland) with a positive vote for a prospective observational study (trial number EKNZ BASEC 2020–00122).
: Written informed consent was obtained from all individual participants included in the study.
: Dr. della Volpe Waizel is member of the Scientific Advisory Board of backlight therapeutics Switzerland.Dr. Valmaggia discloses personal compensation from Heidelberg Engineering and Roche.Dr. Scholl is member of the Scientific Advisory Board of: Boehringer Ingelheim Pharma GmbH & Co; Droia NV; Eluminex Biosciences; Janssen Research & Development, LLC (Johnson & Johnson); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc. Dr. Scholl is a consultant of: Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Tenpoint Therapeutics.Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of Belite Bio (DRAGON trial, NCT05244304; LBS-008-CT02, NCT05266014), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial), ViGeneron (protocol number VG901-2021-A) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561).Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s).
